Bio-Rad Laboratories, Inc. (BIO)

Market Cap	8.03B
Revenue (ttm)	2.67B
Net Income (ttm)	-637.32M
Shares Out	28.69M
EPS (ttm)	-21.82
PE Ratio	n/a
Forward PE	25.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	290,252
Open	283.12
Previous Close	281.02
Day's Range	276.24 - 285.27
52-Week Range	261.59 - 473.50
Beta	0.88
Analysts	Buy
Price Target	421.67 (+50.74%)
Earnings Date	May 7, 2024

About BIO

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety mar...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1952
• Employees: 8,030
• Stock Exchange: NYSE
• Ticker Symbol: BIO

Financial Performance

In 2023, BIO's revenue was $2.67 billion, a decrease of -4.67% compared to the previous year's $2.80 billion. Losses were -$637.32 million, -82.43% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is $421.67, which is an increase of 50.74% from the latest price.

Price Target

$421.67

(50.74% upside)

Analyst Consensus: Buy